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In multiple forms of cancer, constitutive activation of type I IFN signaling is a critical consequence of immune 
surveillance against cancer; however, PBMCs isolated from cancer patients exhibit depressed STAT1 phospho-
rylation in response to IFN-α, suggesting IFN signaling dysfunction. Here, we demonstrated in a coculture sys-
tem that melanoma cells differentially impairs the IFN-α response in PBMCs and that the inhibitory potential 
of a particular melanoma cell correlates with NOS1 expression. Comparison of gene transcription and array 
comparative genomic hybridization (aCGH) between melanoma cells from different patients indicated that 
suppression of IFN-α signaling correlates with an amplification of the NOS1 locus within segment 12q22-24. 
Evaluation of NOS1 levels in melanomas and IFN responsiveness of purified PBMCs from patients indicated 
a negative correlation between NOS1 expression in melanomas and the responsiveness of PBMCs to IFN-α. 
Furthermore, in an explorative study, NOS1 expression in melanoma metastases was negatively associated 
with patient response to adoptive T cell therapy. This study provides a link between cancer cell phenotype and 
IFN signal dysfunction in circulating immune cells.
Introduction
Patients with cancer suffer abnormalities in innate immunity 
exemplified by reduced phosphorylation of STAT1 by PBMCs 
stimulated ex vivo with IFN-α (1). Originally described in patients 
with advanced cutaneous melanoma (1–3), this phenomenon was 
subsequently documented in other cancers including colon and 
breast carcinoma (4). Suppression of phosphorylated STAT1 
(p-STAT1) appears in stage II and deepens with disease progres-
sion. Moreover, although patients with cancer display markedly 
depressed levels of inducible p-STAT1 compared with those of 
healthy donors, dramatic differences can be observed among 
them, while p-STAT1 is generally inducible within a narrow 
range in PBMCs from normal individuals (4). These observations 
suggest that p-STAT1 levels in circulating cells are influenced by 
the biology of cancers, and this may bear clinical relevance, since 
inter-subject variation of p-STAT1 induced in PBMCs by treat-
ment with high-dose IFN-α may predict clinical outcome in mel-
anoma patients (5). Of note, in vitro response of PBMCs to IFN-α 
parallels the in vivo responsiveness of circulating immune cells to 
the same agent given systemically (6).
The mechanism leading to impairment of IFN signaling in 
PBMCs of patients with cancer is unknown, and a link between 
the genetics of a given patient’s cancer and the corresponding 
behavior of circulating cells has not been established. Yet, if such a 
link could be established, PBMCs could serve as useful markers of 
a patient-specific tumor phenotype. This is particularly relevant, 
because increasing attention has been paid to the relationship 
between IFN signatures in the tumor immune microenvironment, 
the prognosis of patients with cancer (7), and/or their respon-
siveness to immunotherapy (8). In parallel with IFN-α signaling 
dysfunction in immune cells, deficiencies in IFN-α responsive-
ness have been documented in melanoma cell lines from patients 
with melanoma. Lesinski et al. (9) observed that melanoma cells 
respond variably to IFN-α, often exhibiting depressed JAK/STAT 
signaling. Interestingly, basal levels of p-STAT3 were inversely cor-
related with IFN-α–induced p-STAT1 (IFN-α-p-STAT1).
Here, we used a Transwell system to screen the effects of a panel 
of 12 melanoma cell lines on PBMCs obtained from healthy volun-
teers. After 7 days of coculture, we stimulated PBMCs with IFN-α. 
We identified two groups of cell lines that reproducibly differed 
in suppressing inducible p-STAT1 in PBMCs. Array comparative 
genomic hybridization (aCGH) pointed at a consistent amplifica-
tion of 12q22-24 in cell lines with the highest immune-suppressive 
activity. This amplification corresponded to higher mRNA levels 
of NOS1, which is hosted within this genomic region. Functional 
studies corroborated the relevance of NOS1 as an inhibitor of 
p-STAT1 induction following IFN-α stimulation. These results 
suggest that NOS1 expression by melanoma cells contributes to 
type I IFN signaling dysfunction in cancer patients and establishes 
a link between the genetics of individual cancers and a circulating 
biomarker of potential clinical utility (Supplemental Figure 15: 
workflow; supplemental material available online with this article; 
doi:10.1172/JCI69611DS1).
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Results
Modulation of IFN-α-p-STAT1 in PBMCs by melanoma cell lines. We per-
formed flow cytometry to screen 25 cell lines for basal and IFN-α–
induced (1,000 IU/ml) p-STAT1 (IFN-α-p-STAT1) levels. Consis-
tent with previous reports (9), basal levels and response to IFN-α 
were heterogeneous among cell lines (Figure 1A, left), in which 
each cell line displayed a highly reproducible and idiosyncratic 
behavior. We selected 12 melanoma cell lines representative of the 
observed heterogeneity and tested them in a noncontact coculture 
Transwell system with PBMCs from healthy individuals (Figure 
1A, bottom). We chose healthy donors in order to exclude any pre-
determined variation in PBMC response due to the cancer-bearing 
status. After 7 days, cell lines and PBMCs from 4 healthy donors 
were separated and stimulated with IFN-α (1,000 IU/ml) in three 
Figure 1
Modulation of IFN-α-p-STAT1 in PBMCs by melanoma cell lines. (A) Top left: Histograms of p-STAT1 levels in 25 melanoma cell lines. Isotype, 
basal, and IFN-α-p-STAT1 are displayed in the top, middle, and bottom panels to exemplify IFN-α-p-STAT1 variability. Bottom left: Transwell cocul-
ture of melanoma cells and PBMCs. Right: IFN-α-p-STAT1 (top) and basal p-STAT1 (bottom) in CD4+, CD8+, and monocyte subsets of PBMCs 
from 4 donors in triplicate experiments after a 7-day coculture with 12 melanoma cell lines (blue bar) or alone (Mono; red bar). (B) Top: Average 
IFN-α-p-STAT1 levels in CD4+, CD8+, and monocyte subsets from 4 donors cocultured with 12 melanoma cell lines or alone, as shown in A. Cocul-
tured results were ranked according to IFN-α-p-STAT1 levels (*P < 0.05, **P < 0.005, and ***P < 0.0005, Wilcoxon test): 5 cell lines with strong 
inhibitory effects (reduction of IFN-α-p-STAT1 by 50% compared with PBMCs cultured alone) were determined to be L-mels, and the rest H-mels. 
Bottom: IFN-α-p-STAT1 in PBMC subsets cocultured with L-mels or H-mels (P = 0.0005, Wilcoxon test). (C) Top: Average IFN-α-p-STAT1 levels in 
L-mels before and after coculture were lower than those in H-mel cell lines (Mann-Whitney U test, P = 0.048 and 0.018) before and after coculture 
with PBMCs (shown for individual cell lines at the bottom). IFN-α-p-STAT1 was enhanced significantly after coculture with PBMCs only in H-mels 
(P = 0.047, Wilcoxon test). (D) IFN-α-p-STAT1 in melanoma cells correlated with the IFN-α-p-STAT1 in respective cocultures of CD4+, CD8+, and 
monocyte subsets (Spearman’s correlation).
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independent experiments. We documented the basal and IFN-α-
p-STAT1 levels in the CD4+ and CD8+ T cells and monocyte mel-
anoma cells (Figure 1A, right). We found that basal and IFN-α- 
p-STAT1 levels were highest in CD4+ T cells, intermediate in CD8+ 
T cells, and lowest in monocytes, consistent with previous reports 
(1, 4). Basal p-STAT1 levels in all PBMC subsets did not differ 
significantly between those cultured alone and those cocultured 
with melanoma cells, while IFN-α-p-STAT1 levels varied greatly 
following a cell line–specific pattern (P = and 0.0001, 0.0001, and 
0.0009 for CD4+ and CD8+ T cells and monocytes, respectively; 
Kruskal-Wallis ANOVA, n = 4) (Supplemental Figure 1). Basal 
p-STAT1 levels in cocultured PBMC subsets varied significantly 
among the 4 donors, but not IFN-α-pSTAT1 levels (P = 0.0001, 
0.0001, and 0.0001 for basal p-STAT1 in CD4+ and CD8+ T cells 
and monocytes, respectively, Kruskal-Wallis ANOVA, n = 12) (Sup-
plemental Figure 2).
IFN-α-p-STAT1 was significantly suppressed by 10 of 12 mela-
noma cell lines, unaffected by one, and enhanced by another. Five 
cell lines suppressed IFN-α-p-STAT1 in PBMCs by more than 50% 
compared with that in culture alone (Figure 1B, top), resulting 
in significantly lower IFN-α-p-STAT1 levels in the three PBMC 
subsets compared with those in other cell lines (P = 0.0005, Wil-
coxon test, n = 12; Figure 1B, bottom). The 5 cell lines were termed 
L-melanomas (further abbreviated as L-mels; lower p-STAT1 levels 
in corresponding PBMCs); the other 7 lines were termed H-mel-
anomas (further abbreviated as H-mels; higher p-STAT1 levels), 
including the one stimulating higher IFN-α-p-STAT1 levels (indi-
vidually named S-melanomas, further abbreviated as S-mels). 
To insure that the results were not due to the skewed generation 
of bovine serum–reactive T cells, we also tested the inhibitory 
effects of two L-mel cell lines (3107 and A375) in the presence of 
autologous serum in 2 healthy volunteers and observed identical 
results (Supplemental Figure 3). These data confirm extensive 
preliminary work in which various culture conditions were tested 
to evaluate the current Transwell method, demonstrating no sig-
nificant differences when bovine serum, autologous, or serum-
free medium was used. Moreover, we found that the proportion 
of immune cell subsets did not change significantly during these 
experimental conditions (Supplemental Figure 4).
L-mel cell lines cultured alone or cocultured with PBMCs dis-
played overall lower p-STAT1 levels than did H-mels (P = 0.048, 
and 0.018, Mann-Whitney U test; Figure 1C, top). In coculture, the 
cell lines responded to IFN-α stimulation by enhancing p-STAT1 
levels; however, the enhancement reached significance only in 
H-mels and not in L-mels (Figure 1C, bottom). Moreover, we 
observed that the responsiveness to IFN-α stimulation correlated 
significantly with the inhibitory responsiveness of IFN-α signaling 
in the three PBMC subsets (Figure 1D; P ≤ 0.001), suggesting that 
the same factors responsible for p-STAT1 modulation in PBMCs 
exert autocrine effects on melanoma cells.
Transcriptional signatures specific for L-mels. Principal component 
analysis (PCA) based on the complete Affymetrix Human Gene 
ST 1.0 dataset naturally segregated the 12 melanoma cell lines 
in L-mels versus H-mels, while S-mels clustered separately (Fig-
ure 2A). Consistently, we observed that average-linkage hierar-
chical clustering segregated L-mels as opposed to H-mels, while 
S-mels clustered separately with one of the L-mel lines (Figure 
2B). Gene enrichment analysis comparing transcriptional differ-
ences between L-mels and H-mels identified 6,771 differentially 
expressed transcripts (ANOVA, cutoff of P < 0.05). Although 
these genes clustered S-mels together with L-mels (Figure 2C), we 
observed a common signature between S-mels and H-mels. The 
Figure 2
Transcriptional signatures specific for L-mels. (A) 
PCA based on global gene expression classified 
12 melanoma cell lines into three groups accord-
ing to immune phenotypes. (B) Unsupervised hier-
archical clustering based on global gene expres-
sion by average linkage. (C) Heatmap based on 
6,771 genes differentially (Student’s t test cutoff of 
P < 0.05) expressed between L-mels and H-mels.
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same 6,771 genes were applied to recluster 41 additional mela-
noma cell lines with 12 cell lines. We observed two clusters: one 
included the 5 L-mels and the other H-mels and S-mels (Figure 
3A). We then arbitrarily selected 3 untested cell lines from each 
group and used the Transwell system to assess the predictive 
power of the gene signature differentiating L-mels from H-mels. 
The 3 cell lines belonging to the L group significantly inhibited 
IFN-α-p-STAT1 in PBMCs, while the 3 lines derived from the H 
group did not (Figure 3B). Ingenuity pathway analysis (IPA) based 
on the same gene set confirmed that the predominantly affected 
pathway was IFN signaling, with reduced expression of IFNRA1, 
IFNRA2, JAK1, and JAK2 by L-mels, corresponding to inhibition of 
the downstream transcription IFN regulatory factors (IRFs) IRF7, 
IRF5, STAT1, and STAT4 (Supplemental Table 1; IPA z score of 
less than –2). In contrast, we found that the top activated path-
way in L-mels was G protein–coupled receptor signaling (Figure 
4), with upregulation of G protein receptors and the downstream 
target transcription factors HNF1A and HNF4A (Supplemental 
Figure 5; IPA z score of greater than 2), which functionally related 
with cellular proliferation and dependence upon STAT3 signal-
ing. Indeed, we observed that several STAT3 target transcripts were 
upregulated in L-mels (Supplemental Table 2).
12q22-24 amplification is a genomic marker for L-mel and targets the 
NOS1 gene. aCGH of the 12 melanoma cell lines provided results 
consistent with the literature (10–13). We observed gains in chro-
mosomes 1q, 3, 6q, 7, 8q, and 20, while losses prevailed in chro-
mosomes 4, 6p, and 10, suggesting that both L-mels and H-mels 
share common genomic characteristics of melanoma. Visually, the 
L group consistently displayed chr12 amplification, while the H 
group was characterized by chr8 amplification (Figure 5A, top). 
Class comparison between the two groups identified ten segments 
that passed the one-way ANOVA cutoff threshold P value of less 
than 0.01, with a symmetrical fold change greater than 2; four of 
these segments were in chr8, five were in chr12, and one was in 
chr10 (Figure 5A, bottom).
One segment (A_14_P105868, region 950, chr12.107491693. 
110237959) passed the stringent cutoff of P < 0.00001 and over-
lapped with two other significantly amplified segments (A_14_
P111446, region_950, chr12.107491693.110237959; and A_16_
P398369, region_958, chr12.117199446-.124525018) covering 
a broad region of 12q22-24 (chr12:105882568-114831260) that 
includes 168 genes, of which 19 overlapped with the 6,771 tran-
scripts differentiating L-mels from H-mels (Figure 5B, top, and Sup-
plemental Table 3). Among them, HNF1A and FOX4N affect G pro-
tein–coupled receptor signaling, the top pathways engaged in the 
L-mel signature (Supplemental Figure 5). Moreover, the NOS1 gene 
was hosted in the same region. We observed amplifications of NOS1 
exclusively in L-mels, while we observed deletions only in H-mels 
(Figure 5B, bottom, and Supplemental Table 4). In parallel, NOS1 
mRNA expression was significantly higher in L-mels compared with 
that in H-mels (Figure 5C, left; P = 0.0001, Mann-Whitney U test) 
and correlated with NOS1 protein levels in 8 representative cell lines 
tested by flow cytometry (r = 0.81, P = 0.032, Spearman’s coefficient; 
Figure 5C, right). Moreover, NOS1 mRNA expression in the 12 mel-
anoma cell lines correlated with suppression of IFN-α-p-STAT1 
in CD4+ and CD8+ T cells and monocytes (P = 0.0003, 0.0002, and 
0.0011, respectively, Spearman’s coefficient; Figure 5D, left) and 
with their own IFN-α response (P = 0202; Figure 5D, right).
Functional validation of NOS1 as a critical factor for melanoma-induced 
immune depression. NOS1 synthesizes NO, which is a free radical 
playing a critical role in various physiological and pathological pro-
cesses. To test whether NOS1 participates in melanoma-induced 
Figure 3
Functional validation of the L-mel signature on 
independent cell lines. (A) Heatmap based on 
the same genes, but including 41 additional mel-
anoma cell lines (red) in addition to the original 
12 (L-mels, green; H-mels including S-mels, blue). 
The 3 red and 3 blue arrows indicate 6 cell lines 
(3 classified as H-mels and 3 as L-mels) randomly 
selected for validation of the predicted modula-
tion on PBMCs according to the 6,771 gene sig-
natures. (B) The 3 lines predicted to be L-mels 
(blue arrows) and a previously tested L-mel (888) 
significantly inhibited IFN-α-p-STAT1 (Wilcoxon 
test, P = 0.0039 for all four L-mels; *P < 0.05; 
**P < 0.005; ***P < 0.0005), while the 3 new (red 
arrows) and the previously tested H-mels did not.
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Figure 4
Signal pathways affected by the L-mel signature. (A) IFN signaling pathway according to IPA, which highlighted JAK1, JAK2, IFNA1, and IFNA2 downreg-
ulation in L-mels (green). (B) G-coupled receptor pathway according to IPA with receptor families. Gi-coupled receptors were upregulated in L-mels (red).
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immune suppression, we administered NONOate, a chemical prod-
uct that slowly releases NO in culture and mimics NOS1 activity. 
NONOate induced a dose-dependent suppression of IFN-α- 
p-STAT1 in CD4+ and CD8+ T cells and monocytes (P < 0.001 for all 
concentrations tested, Wilcoxon test; Figure 6A, left). Conversely, in 
six independent experiments, administration of CarPITO, a scaven-
ger of NO, caused a dose-dependent reversal of the IFN-α-p-STAT1 
suppression in PBMC subsets that was induced by the three L-mels 
888, 3107, and A375 (P = 0.1173, 0.0201, and 0.0184 at 2.5, 5, and 
10 μM; Figure 6A, middle). Administration of L-NAME, a chemical 
inhibitor of all NOS family members (NOS1, NOS2, and NOS3), 
reversed the suppression induced by the three L-mels (P = 0.3038, 
0.0169, and 0.0007 at 250, 500, and 1,000 μM; Figure 6A, right).
Selective inhibitors of NOS1 (NPLA) and NOS2 (1400W) 
reversed the suppression of IFN-α-p-STAT1 induced by the three 
L-mels at concentrations between 50 and 200 μM (P < 0.001 for 
both agents; Figure 6B), suggesting that both NOS1 and NOS2 
contribute to PBMC suppression. Since monocytes present in 
PBMCs might be induced by melanoma cells to produce NOS2 
that could indirectly contribute to p-STAT1 suppression, we 
cocultured purified CD3+ T cells with the three L-mels. We 
found that CD3+ T cells were also susceptible to suppression of 
IFN-α-p-STAT1 (P < 0.01), but to a significantly lesser degree 
than when cocultured with L-mels in the whole PBMC popula-
tion (P < 0.01; Figure 6B, right).
Suppression of IFN-α-p-STAT1 in purified CD3+ T cells was 
reversed by NPLA (P = 0.0005, 0.0006, and 0.0121 at 50, 100, 
200 μM; Figure 6C, left), even at minimal concentrations of 
5 μM, 10 μM, and 20 μM (P = 0.0024, 0.0034, and 0.0024; Sup-
plemental Figure 6, left). In contrast, the NOS2-specific inhibi-
tor 1400W did not significantly affect IFN-α-p-STAT1 at high or 
low concentrations (Figure 6C, right, and Supplemental Figure 
6, right), suggesting that NOS1 is primarily responsible for sup-
pression of IFN-α-p-STAT1 in CD3+ T cells.
Figure 5
12q22-24 amplification is a genomic marker for L-mel and targets the NOS1 gene. (A) Top: Chromosomal amplifications (red) and deletions (blue) 
in L-mels (above) and H-mels (below). Differences between L-mels and H-mels focused on chr8 and chr12 (blue squares). Bottom panel: Ten 
segments (red triangles) identified by ANOVA comparing L-mels with H-mels (cutoff of P < 0.01, fold change of less than –2 or greater than 2). 
The segments are located in chr8, chr10, and chr12 (4, 1, and 5 segments, respectively). (B) Top: Copy number values in chr12q22-24 including 
the most significant segment and 2 other flanking segments in which the NOS1 gene is located (cutoff of P < 0.00001). Bottom: Venn diagram 
assembling 168 genes from 3 overlapping segments in chr12q22-24 with the 6,771 differentially expressed genes between L-mels and H-mels; 
19 were in common between the two platforms, and their symbols are displayed. (C) Left: NOS1 mRNA values in L-mels (blue) were higher than 
those in H-mels (red) (P = 0.001, Mann-Whitney U test). Right: NOS1 protein and RNA correlation in 8 melanoma lines tested by intracellular 
FACS analysis. (D) Left: Correlation between NOS1 mRNA values in melanoma cells (x axis) and IFN-α-p-STAT1 levels (y axis) in corresponding 
cocultured CD4+ and CD8+ T cells and monocytes. Right: Correlation between NOS1 mRNA values in melanoma cells (x axis) and their IFN-α-
p-STAT1 levels (y axis). All correlation analyses in this figure are based on Spearman’s correlation test.
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Figure 6
Functional validation of NOS1 as a factor inducing immune suppression. (A) Left: IFN-α-p-STAT1 
in CD4+ and CD8+ cells and monocytes following inhibition with NONOate (NO donor). Mid-
dle and right: CarPITO (scavenger of NO) and L-NAME (nonselective inhibitor of NOS family) 
induced recovery of CD4+ T cell suppression by 3 L-mels. (B) Left and middle: Selective inhibitors 
of NOS1 (NPLA) and NOS2 (1400W) reversed the suppression of IFN-α-p-STAT1 in cocultured 
PBMC subsets. IFN-α-pSTAT inhibition of PBMC subsets by L-mels was reversed by both NPLA 
(left panel) and 1400W (right panel). (C) Left: NPLA reversed IFN-α-p-STAT1 suppression in puri-
fied CD3+ T cell subsets. Right: 1400W had no effect in the same conditions. (D) Left: Nitration 
in PBMC subsets cocultured with 3 L-mels and one with an H-mel. Middle: Nitration of PBMC 
subsets increased according to the NONOate concentration and was inversely correlated with 
IFN-α-p-STAT1. Right: Reduction of nitration in PBMC subsets by L-NAME. (E) NOS1 genetic 
knockdown cell line 3107s significantly restored IFN-α-p-STAT1 inhibition in CD4+, CD8+, and 
monocyte subsets in a coculture system compared with that in parent cell line 3107 or control 
cell line 3107c (paired Student’s t test, P = 0.003 for both 3107 and 3107c). In all experiments, 
the 3 L-mel cell lines used were 888, 3107, and A375, while the H-mel cell line was 1858. Data for 
L-mels are presented cumulatively for simplicity, although comparable results were obtained with 
each individual cell line. All experiments were repeated at least six times. *P < 0.05, **P < 0.05, 
and ***P < 0.005 were derived from the Wilcoxon test or Spearman’s correlation.
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Nitrotyrosine is considered a marker of NO-dependent redox 
activity and parallels NO levels. We observed that nitration levels 
were significantly higher in CD4+ and CD8+ T cells and monocytes 
cultured with L-mels (888, 3107, and A375-MEL) compared with 
those seen in H-mels (1858-MEL) (P = 0.0003, 0.0003, and 0.0017 
for 888, 3107, and A375-MEL) and were negatively correlated 
with the corresponding IFN-α-p-STAT1 levels in PBMC subsets 
(P < 0.0001, Spearman’s correlation; Figure 6D, left). We found 
that nitration levels were enhanced in PBMCs according to the 
dosage administration of NONOate (P = 0.0039, 0.0039, and 
0.0039 for 250, 500, and 1,000 μM) and inversely correlated with 
IFN-α-p-STAT levels (P = 0.0001; Figure 6D, middle), while they 
were reduced by L-NAME (P = 0.0015, 0.0009, and 0.00102 for 250, 
500, and 1,000 μM,) and inversely correlated with IFN-α-p-STAT1 
levels (P = 0.0031; Figure 6D, right).
To further assess the role of NOS1 in suppressing IFN-α- 
p-STAT1, we applied genetic knockdown technology to the 
strongly inhibitory L-mel 3107 cell line (Figure 6E). We found that 
the levels of IFN-α-p-STAT1 were significantly restored in CD4+, 
CD8+, and monocyte subsets pretreated with shRNA (3107s), but 
not shRNA control (3107c).
Correlation between NOS1 expression by metastatic melanoma and 
responsiveness of circulating PBMCs to IFN-α stimulation ex vivo. Simul-
taneously collected metastatic melanoma samples and PBMCs 
from 9 patients were tested by global transcriptional profiling 
(14). Canonical modulators of IFN-α signaling such as IFNAR2, 
JAK1, STAT1, IRF7, and IRF1 were downregulated in the metasta-
ses and PBMCs compared with the reference PBMCs from healthy 
individuals, while IRF2 and STAT3 were upregulated (Figure 7A, 
left and middle). The degree of deregulation of these factors was 
highly correlated between melanoma and corresponding PBMCs 
(Pearson’s P = 0.0001, n = 63; Figure 7A, right).
We also tested 8 available cryopreserved PBMC samples from 
the 9 patients for p-STAT1, p-STAT3, and p-IRF7 before and after 
IFN-α stimulation (1,000 IU/ml). Both basal and IFN-α-p-STAT1 
levels trended toward an inverse correlation with NOS1 expression 
in melanomas, with IFN-α-p-STAT1 being significantly affected 
in CD8+ T cells (P = 0.0078, Figure 7B, left). We found that basal 
and IFN-α-p-STAT3 did not correlate significantly (not shown); 
however p-STAT3/p-STAT1 ratios were positively correlated with 
NOS1 expression in CD4+ T cells in tumors (P = 0.0242, Figure 7B, 
middle). Moreover, basal IRF7 levels in PBMCs did not vary, while 
IFN-α-pIRF7 inversely correlated with tumor NOS1 expression in 
all subsets and significantly so in CD8+ T cells (Figure 7B, right). 
Interestingly, the correlation between NOS expression and IFN-α- 
p-STAT1 in monocytes was quite modest. Therefore, in PBMC sub-
sets obtained ex vivo, we evaluated the correlation between IFN-α–
induced STAT1 with in vivo NOS2 expression by paired melanoma 
metastases. Surprisingly, NOS2 expression did not correlate with 
IFN-α-p-STAT1 in CD4+ and CD8+ subsets, but it was positively 
correlated in monocytes (Pearson’s r; P = 0.0706, 0, 0.0926, and 
0.0091; Supplemental Figure 7, left). We found no correlation 
between NOS2 expression and IFN-α-p-STAT3/1 or IRF7 in any 
of the three subsets (P = 0.1044, 0.5197, and 0.6175 for IFN-α- 
p-STAT3/1; P = 0.4597, 0.6657, and 0.2282 for IRF7 by CD4+, 
CD8+, and monocyte subsets, respectively; Supplemental Figure 7, 
middle and right), suggesting that regulation of STAT activation is 
multifactorial in vivo and that NOS1-PBMC interactions in vitro 
indicate a significant, but not unique, contribution by cancer cells 
to the regulation of immune activation in vivo.
NOS1 expression by melanoma metastases is associated with immune 
responsiveness to adoptive T cell transfer therapy. We evaluated the 
relationship between NOS1 expression and responsiveness to 
immunotherapy in 113 melanoma metastases excised for the 
expansion of tumor-infiltrating lymphocytes (TILs) to be adop-
tively transferred (15, 16). Of the 113 patients, 24 experienced a 
complete response (CR), 35 had a partial response (PR), and 54 
had no response (NR) according to the response evaluation criteria 
in solid tumors (RECIST).
The distribution of NOS1 expression values in the 113 metasta-
ses was bimodal (P < 0.01, Kolmogorov-Smirnov normality test) 
and naturally ranked the 113 cases into high- and low-expression 
groups according to a mean NOS1 expression of 4.4 (Figure 7C, 
left). The high-expression NOS1 group (n = 56) was enriched with 
NR (CR + PR versus NR = 6 + 16 versus 34, n = 56) compared with 
the low-expression group (CR + PR versus NR = 18 + 19 versus 20, 
n = 57) (P = 0.011, χ2 test). NOS1 expression was inversely cor-
related with therapeutic outcome (P = 0.0001, Spearman’s coef-
ficient rank correlation; Figure 7C, right). NOS1 expression was 
lower in CR patients, intermediate in PR patients, and higher in NR 
patients (mean ± SEM: 4.22 ± 0.04433, 4.333 ± 0.0432, and 4.454 ± 
0.0420 for CR, PR, and NR patients, respectively; P = 0.0003, one-
way ANOVA; Figure 7D, left), and NOS1 expression in CR plus 
PR patients (overall response, OR) differed from that observed in 
NR patients (P = 0.0002; Figure 7D, right). In contrast, we found 
that the expression of NOS2 and NOS3 in 113 metastases was nor-
mally distributed and did not correlate with therapeutic outcome 
(Supplemental Figure 8). However, NOS1 expression correlated 
with NOS2 and NOS3 (r = 0.5616, P < 0.0001, and r = 0.308, 
P < 0.0001 for NOS2 and NOS3; Supplemental Figure 9). Hier-
archical clustering based on NOS1, NOS2, and NOS3 expression 
values segregated the 113 cases into three groups: one with coor-
dinated high expression of all NOS genes and enriched with NRs, 
another with low expression enriched with CR, and a third with 
discordant expression of NOS genes corresponding to a mixture 
of CRs, PRs, and NRs (Figure 7E).
Discussion
This study suggests that NOS1 expression links immune dysfunc-
tion in circulating immune cells with a genetically identifiable 
phenotype of melanoma. We documented that NO produced by 
NOS1-expressing melanoma cells directly inhibits IFN-α signal-
ing in PBMCs in a coculture system and acts as an initiator of the 
expression of other NOS genes in the presence of other immune 
cells. It should be noted that since we used the Transwell system, 
we could not exclude a priori an additional potential role of path-
ways activated by cell-to-cell interactions and, therefore, the in 
vitro culture system might not entirely reflect the in vivo situation. 
In particular, the relationship between NOS1 expression and acti-
vation of STAT1 is exclusive only when observed in vivo, suggest-
ing that this mechanism can independently, but not exclusively, 
affect the immune activation status in vivo. Other factors may 
contribute to this, as suggested by the healthy expression of NOS2 
and NOS3 in vivo (Supplemental Figures 7 and 8). We would like 
to emphasize that this study was primarily aimed at understand-
ing the relationship between cancer genotype and STAT1 activa-
tion potential in circulating cells. Our assessment of  associations 
between NOS expression and cancer phenotype and clinical out-
come produced secondary interpretations about the potential rele-
vance of these findings to the tumor microenvironment. But these 
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should be viewed as preliminary and explorative observations to 
direct future studies. Similarly, the role of NOS1 as a potentially 
predictive biomarker of immune responsiveness to adoptive T cell 
therapy should be seen only as explorative, since no prospective 
validation could be entertained by this purely mechanistic study.
Nevertheless, these findings suggest that melanoma cell–
derived NO is a crucial modulator of immune function in the 
tumor microenvironment and provides a potentially novel target 
for immunotherapy. It should be emphasized that the relation-
ship between activation of STAT1 in circulating PBMCs and the 
Figure 7
NOS1 expression by melanoma metastases. (A) mRNA levels of IFN-α–related signaling genes in 9 melanoma metastases (left) and simulta-
neously collected autologous PBMCs (middle) presented as fold change compared with healthy donors’ PBMCs. Right: Scatter plot displaying 
correlative values for transcripts shown in the previous two panels comparing melanoma metastases (y axis) and PBMCs (x axis); n = 63. (B) 
Scatter plots correlating ex vivo IFN-α-p-STAT1 (left), IFN-α-p-STAT3/p-STAT1 (middle), and IFN-α-pIRF7 (right) with NOS1 expression in 8 
available PBMCs (y axis). (C) Left: lack of normal distribution of NOS1 expression in melanoma metastases (P < 0.01, Kolmogorov-Smirnov 
normality test) and ranking of the 113 cases into high- and low-expression groups according to the mean NOS1 expression value (4.40). Right: 
NOS1 expression in melanoma was inversely correlated with therapeutic outcome (Spearman’s rank correlation coefficient). The high-expression 
NOS1 group was significantly enriched with NR cases (P = 0.011, χ2 test); (D) Left: NOS1 expression in 113 melanoma metastases from patients 
receiving adoptive TIL therapy segregated according to response to therapy (CR, PR, and NR; P values refer to one-way ANOVA). Right: NOS1 
expression in overall response (CR + PR) compared with NR cases (unpaired Student’s t test). (E) Hierarchical clustering of the 113 metastases 
according to NOS1, NOS2, and NOS3 displaying three groups, one with concordantly high expression of the 3 NOS genes and enriched in NRs, 
the other with low expression, and the third with discordant expression. All correlative analyses are based on Pearson’s correlation test.
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in PBMCs: (a) altered IFN-α-p-STAT1 is at least in part dependent 
upon soluble factors released by cancer cells; (b) this effect is idio-
syncratic, as cancer cells displaying the strongest immune sup-
pressive activity also displayed a distinct phenotype both at the 
functional (decreased IFN-α-p-STAT1, Figure 1C) and transcrip-
tional levels (Figure 2); (c) the idiosyncratic behavior could be tied 
to specific genetic characteristics of the melanoma cell lines. Copy 
number analysis identified 12q22-24 amplification as a genomic 
marker of the immunosuppressive phenotype (Figure 5); (d) the 
genomic imbalances associated with the immune suppressive 
phenotype pointed to NOS1 as a factor for melanoma-induced 
immune suppression (Figure 5). NOS1 expression was validated 
in vitro as a determinant of immune cell dysfunction (Figure 6); 
(e) a relationship was established in vivo between NOS1 expres-
sion in tumors and immune dysfunction of circulating immune 
cells (Figure 7, A and B); (f) the link between NOS1 expression by 
cancer tissues and immune dysfunction of circulating cells could 
be expanded to a broader interpretation of a poor prognosis can-
cer phenotype that we recently described as being characterized by 
an enrichment of Th17 signatures, activation of WNT signaling, 
and decreased responsiveness to adoptive T cell immunotherapy; 
indeed, NOS1 expression was strongly enhanced in melanoma 
metastases bearing this phenotype (Supplemental Figure 10 and 
ref. 13). It is unclear whether the postulated systemic effects pro-
moted by NOS1 secretion by tumors sufficiently alter the func-
tion of nonantigen-specific T cells to indirectly affect the migra-
tion of immune cells, including those relevant to cancer rejection, 
by a general mechanism of immune suppression. This is a likely 
possibility, considering the depletion of Th1 signatures and the 
low expression levels of CD4 and CD8 mRNA in NOS1-express-
ing tumors according to a previously described characterization 
of melanoma metastases (13); (g) NOS1 expression by tumor 
tissues also appeared to be related to immune responsiveness to 
adoptive TIL therapy (Figure 7, C and D), and an inverse correla-
tion was observed between NOS1 expression by metastases and 
IFN-α-p-STAT3/p-STAT1 and p-STAT3 levels (another impor-
tant marker of cancer immune dysfunction) (9, 35–39). It should 
also be emphasized that this study focused on cancer genotypes 
likely to initiate immune suppression, while other mechanisms 
mediated by a bystander immune suppressive mechanism such as 
myeloid-derived suppressor cells or tumor-derived mesenchymal 
stem cells may further modify the effects of cancer cells within 
the tumor microenvironment. This is suggested by experiments 
showing that purified T cell subsets lacking other suppressive 
mechanisms could still be inhibited by L-mels. This effect could 
be reversed only by the NOS1 selective inhibitor NPLA, but not 
by the NOS2 inhibitor 1400W. When T cells were mixed with 
monocytes, the T cell inhibition was stronger. Furthermore, the 
NOS2-specific inhibitor 1400W partially reversed the inhibition 
(Figure 4). Thus, melanoma-generated NOS1 might be critical in 
vivo for cancer-related immune suppression, and NOS2 produced 
by monocyte subsets, including MDSCs, amplified the inhibitory 
function of L-mels through the NOS1 product as a secondary, yet 
important, mechanism.
An interesting observation was the predominant effect of NOS1 
expression on immune dysfunction compared with the current 
focus of the literature on NOS2 (inducible NOS) as an in vivo 
marker of immune dysfunction in breast and prostate cancer 
(40, 41). This discrepancy could be explained in two ways. First, 
melanoma derives from melanocytes that are neuroectodermal 
cancer-bearing status was observed exclusively from stage II, and it 
was most prominent after stage III. This study, therefore, assessed 
the relationship between cancer genotype and STAT1 activation 
in circulating cells at the later stages. We cannot conclude that 
the information obtained could also be extrapolated to the early 
phases of tumor/immune cell interactions in the microenviron-
ment of primary tumors.
There has been growing interest in a reclassification of cancer 
based on immunologic parameters (8, 17). Although the weight 
that cellular immune infiltrates bear on the natural history of mel-
anoma has been long known (18, 19), this observation was recently 
characterized in greater detail and expanded to other cancer types 
(7, 20, 21). In particular, it has been shown that the type and func-
tion of immune infiltrates and the immune texture in which they 
present bear prognostic power beyond the classic tumor, node, 
metastasis (TNM) staging (7), which does not take into account 
specific immunologic signatures (22). This relationship between 
immune phenotype and prognostic connotation pertains to most 
cancers (8) and is predictive of the responsiveness of cancer to 
immunotherapy (8, 23–25). While a worldwide effort is currently 
being made to validate the observation at multinational and multi- 
institutional levels, work is also being done to identify (a) genetic 
determinants that could explain the cancer phenotypes and (b) 
biomarkers detectable in the peripheral circulation that could be 
linked to this prognostic phenotype thus far identifiable only in 
excised tumor tissue.
Parallel with and separate from these efforts are attempts by oth-
ers to characterize the immune phenotype of cancer patients by 
evaluating the immunologic characteristics of circulating immune 
cells (1, 3, 4, 26–32). Among the various markers of immune dys-
function associated with cancer-bearing status, the level of IFN-α- 
pSTAT1 in PBMCs was a reproducible parameter that was first 
documented in melanoma patients (1, 3, 28) and subsequently in 
patients with breast and colon cancer (4).
Although variation in IFN-α-p-STAT1 in PBMCs might be 
related to individual genetic characteristics that could predispose 
to the development of cancer, we believe that such dysfunction is 
primarily due to the cancer-bearing status for two reasons: (a) such 
variation is not observed in normal healthy individuals (of whom a 
proportion will eventually develop cancer); and (b) the alterations 
appear after stage II and worsen along with disease progression (4). 
It is important to note that although average patients with can-
cer experience a significant stage-dependent decrease in IFN-α- 
p-STAT1 compared with healthy individuals, a wide variation is 
observed among them, with some patients maintaining a normal 
pattern of responsiveness even at a late stage. The latter observa-
tion suggests that individual cancers may have distinct effects on 
circulating cells, perhaps through the release of immune regulatory 
factors. Here, we related phenotypic and genetic characteristics of 
melanoma cells with their effects on PBMCs in an in vitro model. 
We elected to test the effect of melanoma cells on PBMCs obtained 
from normal healthy volunteers to avoid confounding factors 
related to intrinsic genetic or acquired determinants of PBMC 
behavior in cancer patients, therefore testing exclusively whether 
cancer cells can determine immune dysfunction. We used cell 
lines belonging to a collection that was expanded from melanoma 
metastases at the Surgery Branch of the NCI and extensively char-
acterized according to their genotype and phenotype (13, 33, 34).
The current study, based on an in vitro Transwell system, pro-
vides a few insights about determinants of immune dysfunction 
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Dye 670 rabbit anti-mouse (1:400, 3068-1; EPITOMICS). For the nitroty-
rosine assay, antinitrotyrosine antibody (Millipore) was added according to 
the manufacturer’s instructions and incubated at 4°C overnight.
RNA interference. To inhibit the efficiency of human NOS1 expression 
in the 7-day coculture system, we used the shRNA expression constructs 
HSH011865-HIVmH1 and control chRNA (GeneCopoeia). Stable cell lines 
expressing shRNA or chRNA were selected by puromycin. Western blot and 
quantitative PCR (qPCR) analysis were performed to measure the knock-
down efficacy in the melanoma cell line 3107 according to the percentage 
of reduction in mRNA expression, comparing shRNA with control (Sup-
plemental Figures 12–14). For qPCR analysis, total RNA was isolated from 
cultured cells using an RNeasy Mini Kit (QIAGEN). cDNA was reverse tran-
scribed from 1 μg of RNA using the iScript cDNA Synthesis Kit (Tiangen), 
and SYBR green–based real-time PCR was performed using the Mx3005p sys-
tem (Stratagene). The primers used for NOS1 were forward: 5′-CAGAGGAT-
GGCAGTCTGTTTC-3′; reverse: 5′-CTCAAGAGCACTGGATCTCAG-3′; and 
the primers for GAPDH were forward: 5′-GAACGGGAAGCTCACTGG-3′; 
reverse: 5′-GCCTGCTTCACCACCTTCT-3′ (Invitrogen).
Western blotting was performed using rabbit polyclonal anti-nNOS 
(Santa Cruz Biotechnology Inc.) at a 1:1,000 dilution and mouse mAb 
against GAPDH at a 1:5,000 dilution. Secondary antibodies used were per-
oxidase-conjugated anti-rabbit IgG and anti-mouse IgG (Bioss), respec-
tively, at a 1:3,000 dilution. Blots were scanned, and immunoreactive bands 
were quantified using Quantity One Software (Bio-Rad). NOS signal inten-
sities in silenced and control cells were normalized to GAPDH values.
Gene expression profiling. Total RNA from melanoma cell lines and patients’ 
melanoma metastases was extracted using an miRNeasy Mini Kit (QIAGEN) 
(13). cDNAs were fragmented, biotinylated, and hybridized to the GeneChip 
Human Gene 1.0 ST Arrays (Affymetrix WT Terminal Labeling Kit). Expres-
sion data were normalized using the RMA algorithm (Partek Inc.). Data were 
log2 transformed for parametric analysis. All analyses were performed using 
the Partek Genomic Suite. Principal component analysis (PCA) was applied 
for visualization based on the complete dataset. Class comparison was based 
on ANOVA, encompassing variations related to batch effect and other hid-
den variables. Heatmaps are presented based on Partek visualization pro-
grams. The functional interpretation of gene signatures was executed using 
IPA 3.0 (http://www.ingenuity.com). Microarray data were deposited in the 
Gene Expression Omnibus (GEO) database (GEO GSE44851).
The RNA from 9 patients’ PBMC samples was obtained from the Uni-
versity of Virginia Medical Center (14). Samples were labeled with Cy5 and 
mixed with a Cy3-labeled reference consisting of pooled PBMCs from 5 
normal donors obtained from apheresis and hybridized to in-house–
printed whole-genome human 36K oligo arrays, representing 25,100 
unique human genes (Operon Human Genome Array-Ready Oligo Set, 
version 4.0). Gene expression values were displayed as log2-transformed 
fluorescence intensity ratios of red (samples) to green (PBMCs reference). 
Microarray data were deposited in the GEO database (GEO GSE32611).
CGH assay and analysis. Genomic DNA was isolated from the melanoma 
cell lines and PBMCs of a healthy female donor using the QIAamp DNA 
Mini Kit (QIAGEN), and 1.5 μg was fragmented, labeled, purified, and 
hybridized to Agilent 2 × 105 K arrays according to the Agilent Oligo Nucle-
otide Array–Based CGH for Genomic DNA Analysis (version 6.2.1) proto-
col. Data were extracted using Agilent’s Feature Extraction Software. Copy 
number variation was measured according to the Partek Genomic Suite. 
After circular binary segmentation normalization, copy number gains and 
losses were detected using a hidden Markov model algorithm in the Partek 
copy number workflow for unpaired samples. Amplifications were defined 
as segments with log2 ratios greater than 0.15. Deletions were defined as 
segments with log2 ratios less than –0.3. Segments were defined as regions 
that differed from neighboring regions by at least 10 markers. The regions 
cells, and NOS1 is generally expressed by such lineage; thus, a lin-
eage-specific bias may explain this finding. Second, the in vitro 
model suggests that NOS2 participates in the immune suppres-
sive activity through activation of the monocyte population in 
PBMCs (Figure 6). This also corresponded with a correlation we 
observed in vivo among 113 melanoma cases, in which NOS1 and 
NOS2 appeared to be coexpressed, whereas such a correlation was 
not observed in pure melanoma cells cultured in vitro (data not 
shown). Thus, our observation suggests that, at least in melanoma, 
NOS1 takes the driver’s seat to induce immune suppression, which 
is subsequently amplified by inducible NOS (NOS2).
In summary, this study provides a possible link between some of 
the genetic and phenotypic characteristics of cancer cells and the 
immune alterations observable in the peripheral circulation. This 
link provides prognostic and predictive implications for following 
the natural course of cancer progression.
Methods
Cell lines and cell culture. Melanoma cell lines expanded from melanoma 
metastases at the Surgery Branch of the NCI and extensively characterized 
(13, 33, 34) were maintained at 37°C in complete medium (RPMI 1640 
with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml 
streptomycin) in humidified 5% CO2 incubators and passaged twice per 
week by trypsinization.
PBMCs were collected from healthy blood donors at the Department of 
Transfusion Medicine, Clinical Center, NIH, isolated by density gradient 
separation (Ficoll-Hypaque; Sigma-Aldrich), and stored at –80°C. CD3+ 
T cells were isolated by a Pan T cell isolation kit II (Miltenyi Biotec) 
through an autoMACS Separator (Miltenyi Biotec). For coculture, 5 × 104 
melanoma cells were seeded in 6-well plates with 2 ml medium overnight. 
The Transwell was then inserted (BD Falcon TM inserts), and 2 × 105 
thawed PBMCs were added. The Transwells were kept in the incubator for 
7 days before testing. Day 7 was chosen based on the optimal distribution 
of p-STAT1 variance detected in preliminary time course studies demon-
strating that suppression occurred after day 5 and reached a plateau on 
day 9 (Supplemental Figure 11). The chemicals NPLA, DETA NONOate 
(Cayman Chemical), CarPITO, L-NAME, and 1400W (Sigma-Aldrich) were 
stored in DMSO and dissolved in medium for immediate use.
Cell staining and flow cytometric analysis. Phosphorylation assays were per-
formed as previously described (42). PBMCs were harvested into two tubes 
at 37°C; the one for basal p-STAT1 assessment was immediately fixed in 
3% PFA for 30 minutes, and the other was kept at 37°C while stimulated 
with 1,000 U/ml IFN-α-2b (R&D Systems) for 23 minutes and then fixed in 
PFA. Permeabilization was performed with 100% methanol at –20°C over-
night. Melanoma cells were harvested using the nonprotolytic cell detach-
ment solution Detachin (Genlantis) and treated in the same manner as 
the PBMCs. Phosphorylation staining was done using antibodies against 
p-STAT1 (Tyr701) Alexa Fluor 647, p-STAT3 (Tyr705) PE, p-IRF7 (p-S477/
p-S479) Alexa Fluor 647, and antibodies against CD4-FITC, CD3-PerCp, 
STAT1-PE, STAT3-APC, and IRF7-PE (all from BD Biosciences) after titra-
tion by incubation for 1.5 hours at room temperature. Samples were then 
washed and tested by flow cytometry (BD FACSCalibur). Data were ana-
lyzed by FlowJo software (Tree Star Inc.). IFN-α-p-STAT1, basal p-STAT1, 
p-STAT3, and p-IRF7 levels in PBMCs were calculated as the mean fluo-
rescence of phosphorylated markers. For melanoma cells, IFN-α-p-STAT1 
was assessed as fold change FIFN-α/Fbasal, where FIFN-α and Fbasal represent the 
mean fluorescence of p-STAT1 in the presence or absence of stimulation, 
since basal p-STAT1 levels varied among melanoma cell lines. For the NOS1 
expression assay, NOS1 mAb (Epitomics, Abcam) was diluted 1:400, incu-
bated at 4°C overnight, and followed by a second antibody staining with 
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identified were annotated using NCBI’s RefSeq hg19. Microarray data were 
deposited in the GEO database (GEO GSE44850).
Clinical samples. Nine paired melanoma and PBMC samples were obtained 
from the Hematology Oncology unit at the University of Virginia Medical 
Center before IL-2 treatment. Patients were histologically confirmed as having 
metastatic malignant melanoma. Exclusion criteria included pregnancy, ische-
mic heart disease, brain metastasis, or requirement for corticosteroids (14).
Pretreatment snap-frozen tumor biopsies from 113 melanoma patients 
were obtained from the Surgery Branch of the NCI. These patients were 
treated under five consecutive phase II clinical trials for adoptive therapy 
of autologous TILs (15, 16). Response (CR, PR, or NR) was assessed using 
the RECIST guidelines starting approximately 4 weeks after TIL adminis-
tration and at regular intervals thereafter. Among 113 patients, 24 achieved 
a durable CR (21%), 34 had a PR (30%), and 55 had NR (49%). A PR or NR 
was considered an overall noncomplete response (non-CR, PR+NR, 79%). 
See Supplemental Methods for more details.
Statistics. All data were tested for normality using the Kolmogorov- 
Smirnov test to decide whether parametric or nonparametric statistical 
tests were to be applied. Parametric unpaired tests included Pearson’s pro-
duct-moment correlation coefficient (r, correlation between two variables), 
an unpaired Student’s t test (comparison of two population means), and 
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